Introduction
For a number of years platinum based chemotherapeutic regimens have been the mainstay for the management of epithelial ovarian cancer, 1 testicular cancers, head and neck and a number of other solid tumor types. 2 Cisplatin and carboplatin are frequently used in combination chemotherapy and their antitumor activity contributed significantly to the improvement in survival rates for patients with ovarian and testicular cancers when they were first introduced into the clinic. More recently, the platinum analogue oxaliplatin has been developed and is now licensed for use in metastatic colon cancer in the US. 3 cisplatin carboplatin oxaliplatin
Scheme 1. Platinum compounds currently used in cancer therapy
However, in spite of their well-deserved place as main players in currently used chemotherapeutic regimens, resistance to platinum agents is a well-documented and unfortunate drawback in their use. In particular, the poor 5 year survival rates seen in epithelial ovarian cancer are at least partly attributed to the development of platinum resistance. 4 Moreover, a large body of laboratory and clinically based evidence has sought to clarify and understand the molecular basis for platinum resistance in tumors. [4] [5] [6] Undoubtedly, a major aim of current anticancer drug development programs is to isolate and identify new compounds with the ability to overcome drug resistance, whilst still maintaining the potent antitumor activities of agents like cisplatin.
In this context, trans-configured platinum compounds have found increasing interest, and a number of promising drug candidates could be identified. 7 as for example Kelland's Pt(IV) complexes bearing NH 3 and aliphatic amines in trans position to each other. 8 Farrell introduced mixed ligand PtCl 2 (L 1 )(L 2 ) complexes where L 1 and L 2 can be both aromatic nitrogen heterocycles or one of the ligands can be ammine or a sulfoxide. 9 Similarly, Navarro-Ranninger's group successfully developed compounds bearing branched aliphatic amines as ligands, 10 and Natile introduced imino-type ligands, which were synthesised in the coordination sphere of the ligand by addition of an alcohol to a coordinated nitrile, 11a others by condensation of acetone with a platinum-ammine precursor.
11b Scheme 2. General strategy for the synthesis of platinum(II) oxadiazoline complexes.
In the framework of our research, we now found an new class of trans-configured platinum(II) compounds whose in vitro properties suggest good potential for the development of new therapeutics that are able to overcome the resistance against conventionally used platinum based antitumor agents: The modular synthetic strategy applied leads to structures with 4 to 7 sites of diversity and potentially lends itself for a combinatorial chemistry approach. The coordination sphere around the Pt (and thus the principal DNA interaction capacity) can be kept constant, while pharmacologically relevant parameters such as solubility, polarity, charge distribution, pK, logP or the transport properties can be addressed by the substitution pattern in the remote periphery of the complex. The heterocyclic ligands are designed to allow for additional interactions: e.g.
aromatic substituents attached to the five membered ring could intercalate into the DNA and thus strengthen the interaction and circumvent repair mechanisms the Pt-resistant cells developed. Additionally, the ligand reactivity (e.g. N-O bond cleavage in a reducing environment) could cause secondary DNA damage. In oxygen-deficient cancer tissues this could offer an additional reaction pathway that takes place in cancer cells but less so in normal cells. It has also been shown that the synthetic strategy can be extended to analogous Pt(IV) compounds 12 and Pt(II) compounds bearing other ligands such as sulfoxides, 13 so there is future scope for further optimization of the new lead structure.
Results and Discussion

Synthesis and characterization of the platinum compounds
The synthesis of the platinum(II) mono-oxadiazoline and platinum(II) bis-oxadiazoline complexes was achieved by cycloaddition of nitrones to PtCl 2 (nitrile) 2 compounds, as shown in Scheme 2. The structure of the compounds prepared is shown in Scheme 3, together with the compound numbering.
Scheme 3.
Structures of the compounds prepared, together with the compound numbering. Our previous work has shown that ortho protons of the coordinated nitrile report most sensitively about the coordination geometry. In the cis complex, these protons are shielded from the magnetic field and the signals are shifted to low ppm values (7.17 for PhCN compared to 7.68 ppm in the trans complex or 7.60 ppm in the uncoordinated nitrile). 15 In both 3 and 6 no such shielding is observed and the respective protons appear at similar ppm values as the free nitriles, in agreement of a proposed trans geometry of these complexes. It was also shown previously that cis-PtCl 2 (nitrile)(oxadiazoline) complexes can be prepared, but this requires the use of cis-PtCl 2 (nitrile) 2 as a precursor, and the resulting complexes are not stable and decompose readily in solution. 15 Finally, the synthesis of the monooxadiazoline complex derived from 1 was attempted but not successful. Due to the poor solubility of 1 the cycloaddition is significantly less selective and only mixtures of monoand bis-oxadiazoline complexes were obtained. 
Solubility and stability studies
The solubility of 4, 5 and 7 was investigated gravimetrically in distilled water, and compared with the solubility in phosphate buffered saline and isotonic saline (0.9g/ml) by UV spectroscopy. The solubility of all compounds was found to be similar and in an order of 0.5 to 4 mg/ml. The solubilities are thus comparable to the one of cisplatin of 1 mg/ml. 18 Since DMSO has been used for the preparation of stock solutions, the stability of 1 -7 in d 6 -DMSO was studied using 1 and alkaline medium. The alkaline medium was used with the idea in mind that the phenolic OH group can be deprotonated quite easily and this could alter the solubility, the chemical and pharmacological properties of the platinum complex.
In vitro activities
The in vitro antiproliferative activity of the compounds was determined by means of a colorimetric microculture assay technique (MTT assay), as described in the experimental section. Typically, the data shown indicate the somewhat higher potency that cisplatin has over carboplatin, which is a repeatable finding throughout the literature. Apart from 7, the compounds in this study showed comparable, and against SW948 even superior activity in comparison with the reference compound cisplatin.
Importantly, against platinum-resistant cell lines the activity of 5 is essentially retained. The same holds true for 4 and 5 when tested in PEO1cisR, but 4 is less active against the PEO1carboR whereas 6 becomes even more active. 5 is comparable to cisplatin in potency being slightly less potent in PEO1 cells but more potent against the colon cancer cell line SW948. 7 is similar in potency to carboplatin, 6 and 4 occupy an intermediate position.
Importantly, 6 appears to be more active in the PEO1CarboR cell line that in the parental cell line. Cisplatin and carboplatin were made up as stock solutions in sterile aqueous 0.9% w/v NaCl (saline solution) and diluted in tissue culture medium to give the required final concentrations for the MTT assay. Compounds 4 -7 were generally used as stock solutions made up in DMSO and then subjected to further dilution as for cisplatin and carboplatin.
We also used 4 as an aqueous stock solution and found that there was no significant variation in the cytotoxicity testing when compared with a DMSO stock solution.
Cell cycle analysis
For the PEO1 parental cells the cell cycle perturbation we saw following a 48h incubation with 2.5µM cisplatin is a characteristic G 2 M blockade of the cell cycle, relative to control untreated cells (see Figure 1) . The effect of cisplatin in the carboplatin resistant platinum compounds (such as cisplatin) has been reported by others. 21 We plan to evaluate in vivo activity of compounds 5 and 6 in platinum resistant ovarian cancer xenograft models. The effects of platinum compounds on cell cycle has been looked at in some detail by others 22 and can provide valuable information on the mechanism of action of platinum based cytotoxic compounds. Of great interest are our preliminary experiments that have addressed the issue of cell cycle blockade. Whilst cisplatin predictably gave rise to a G 2 M blockade as seen by others, 23 we were unable to see significant changes in cell cycle apart from a slight accumulation of sub-G 1 and G 1 when cells were treated with compound 5 under the same experimental conditions. This is in contrast to the findings of others who have looked at the effects of trans platinum compounds 22 and see prolonged S-phase and G 2 M phase arrest. They have studied these effects over a more prolonged time period than in the current study i.e. 24-96 h time points as opposed to the 24 h and 48 h time points we used. It may well be that cell cycle perturbations due to treatment with compound 5 will be manifest if we look at longer treatment times. However, our data provide prima facie evidence that the oxadiazoline containing trans platinum compounds differ from cisplatin and carboplatin in their cell cycle effects. Our studies are currently ongoing to elucidate the cell cycle blockade effects of the oxadiazoline trans platinum compounds used in the present study.
Experimental Section
Materials and Instrumentation. Acknowledgement. We are grateful to the EPSRC for the provision of a studentship and the Proof of Concept Fund of the University of Surrey for supporting of this work.
Preparation of the trans-[PtCl 2 (nitrile)(oxadiazoline)] complexes.
Trans-[PtCl 2 (PhCN){N=C(Ph)-O-N(Me)-CH(p-HO-C 6 H 4 )}], trans-(benzonitrile)-
dichloro[2,3-dihydro-3-(4-hydroxyphenyl)-2-methyl-5-phenyl-1,2,4-oxadiazole-
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